neuroClues, a French-Belgian MedTech startup empowering clinicians with biomarkers allowing them to identify neurological disorders years before visible symptoms, has raised a €10 million Series A, along with additional non-dilutive funding, bringing the total capital raised by the company to €25 million.
The round is led by Teampact Ventures, White Fund and the EIC Fund (European Innovation Council), with participation from existing investors (InvestBW, Leansquare, Wallonie Entreprendre) and the support of Olivier Legrain, Chairman of the Board and CEO of IBA.
“This Series A validates our technology and our ability to execute. CE certification in five months. First commercial deployments within weeks. A normative database project with 25,000 participants. Today, we give clinicians an objective way to assess neurological anomalies. As our dataset grows, our solution will help them identify specific pathologies earlier and more precisely than ever before. That is where we are headed,” said Antoine Pouppez, CEO, neuroClues.
Powered by P3Lab and founded in 2020 by Antoine Pouppez, Pierre Daye, and Pierre Pouget, neuroClues develops and commercialises a compact, non-invasive, CE-marked (Class IIa) medical device that records and analyses eye movements to extract objective and reproducible biomarkers, supporting clinicians in the diagnosis and monitoring of neurological disorders in clinical practice.
According to the company, neurodegenerative diseases are increasingly prevalent, affecting 1 in 3 people while remaining difficult to diagnose. neuroClues warns that the number of people affected by Parkinson’s disease worldwide is expected to double to 13 million by 2040. It also states that around one in five patients is still misdiagnosed, and by the time the disease is correctly identified, irreversible brain damage has already occurred, leading to a loss of 65% of affected neurons.
The startup states that clinicians still rely mostly on clinical observations with no quantitative output, such as the “follow my finger” test, and advanced technologies such as imaging are expensive, not widely accessible and often fail to detect abnormalities at early disease stages.
neuroClues has developed a portable, CE-marked class IIa medical device that quickly extracts neurological biomarkers from eye movements. A compact system captures high-speed infrared images of each eye as the patient performs simple visual tasks. Proprietary AI algorithms then compute objective, reproducible biomarkers.
“Its constraint-free, plug-and-play design with immediate integration in the clinical workflow brings results in minutes (remote interpretation possible), providing critical clues within the consultation time, not months after,” mentioned the company in the press release.
neuroClues assists clinicians in objectively evaluating neurological anomalies, replacing the subjective “follow my finger” test with quantified, reproducible data.
As the platform gathers clinical data on a large scale, it aims to support the identification of specific conditions: differentiating Parkinson’s from atypical Parkinsonisms, highlighting early signs of Alzheimer’s, and detecting concussion-related impairments. Each device deployed makes the platform more intelligent.
The company obtained its CE certification in January 2025. It reported that within months, over 30 devices were deployed across France, Belgium, Italy, Germany, Switzerland, the Netherlands, and the United Kingdom, in university hospitals, private neurology practices, and research centres. The company also reports growing inbound demand from clinicians who have seen the device at congresses or referenced by peers.
According to the company, this commercial traction is supported by several clinical and institutional milestones. These include integration into the Paris Brain Institute’s (ICM) clinical cohorts, such as the Iceberg study on Parkinson’s disease, and selection for the mega-cohort (25,000 participants), which will develop the first large-scale normative database of oculomotor biomarkers.
The company also states it was chosen by Bpifrance’s National Prevention Accelerator, supporting the commercialisation with dedicated assistance. Additionally, it was part of an official French presidential delegation to India, fostering strategic partnerships with leading institutions such as AIIMS.
neuroClues has appointed Bart Stulens, former VP of Neuromodulation EMEA at Medtronic, as Chief Commercial Officer. The company is actively expanding its commercial team across Europe, with recruitment underway in France and distributor agreements either signed or under discussion in the EMEA region.
It has also opened a limited tranche of up to €1.5 million on LITA, the European impact investment platform, enabling citizens and individual investors to participate directly in this round under the same terms as institutional investors.
Read the orginal article: https://www.eu-startups.com/2026/04/neuroclues-raises-e10-million-series-a-to-become-the-brains-stethoscope-for-early-diagnosis-of-neurological-disorders/
